Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

Vaccine

Volumn 29, Issue 40, 2011, Pages 7067-7074

  Fomsgaard, Anders ^a   Karlsson, Ingrid ^a   Gram, Gregers ^a   Schou, Christian ^a   Tang, Sheila ^a   Bang, Peter ^a   Kromann, Ingrid ^a   Andersen, Peter ^a   Andreasen, Lars Vibe ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Adjuvant; AIDS; HIV 1; Therapeutic vaccine

Indexed keywords

ADJUVANT; CAF01; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DEVELOPMENT; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; HLA SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPEATED DRUG DOSE; SINGLE DRUG DOSE; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DOGS; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; GLYCOLIPIDS; HIV INFECTIONS; HIV-1; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; IMMUNIZATION; MALE; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PEPTIDES; QUATERNARY AMMONIUM COMPOUNDS; SWINE; SWINE, MINIATURE; T-LYMPHOCYTES, CYTOTOXIC; TOXICITY TESTS;

EID: 80052317836     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.025     Document Type: Article

References (37)

1. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(January (1)):11-23.
2. Shen L., Peterson S., Sedaghat A.R., McMahon M.A., Callender M., Zhang H., et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14(July (7)):762-766.
3. Rugg D., Marais H., Carael M., De Lay P., Warner-Smith M. Are we on course for reporting on the millennium development goals in 2015?. J Acquir Immune Defic Syndr 2009, 52(December (Suppl. 2)):S69-S76.
4. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010; 2010 [cited; Available from: .]. http://www.unaids.org/globalreport/global_report.htm.
5. Autran B., Carcelain G., Combadiere B., Debre P. Therapeutic vaccines for chronic infections. Science 2004, 305(July (5681)):205-208.
6. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10(December (12)):1359-1365.
7. Corbet S., Nielsen H.V., Vinner L., Lauemoller S., Therrien D., Tang S., et al. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol 2003, 84(September (Pt. 9)):2409-2421.
8. Thorn M., Tang S., Therrien D., Kloverpris H., Vinner L., Kronborg G., et al. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007, 115(June (6)):757-768.
9. Kloverpris H., Karlsson I., Bonde J., Thorn M., Vinner L., Pedersen A.E., et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009, 23(July (11)):1329-1340.
10. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3(9):e3116.
11. Vangala A., Kirby D., Rosenkrands I., Agger E.M., Andersen P., Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 2006, 58(June (6)):787-799.
12. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718(December (1-2)):22-31.
13. Korsholm K.S., Agger E.M., Foged C., Christensen D., Dietrich J., Andersen C.S., et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007, 121(June (2)):216-226.
14. Christensen D., Korsholm K.S., Rosenkrands I., Lindenstrom T., Andersen P., Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007, 6(October (5)):785-796.
15. Gram G.J., Karlsson I., Agger E.M., Andersen P., Fomsgaard A. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One 2009, 4(9):e6950.
16. Christensen D., Agger E.M., Andreasen L.V., Kirby D., Andersen P., Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009, 19(1):2-11.
17. Perez C.L., Larsen M.V., Gustafsson R., Norstrom M.M., Atlas A., Nixon D.F., et al. Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol 2008, 180(April (7)):5092-5100.
18. Malhotra U., Holte S., Zhu T., Delpit E., Huntsberry C., Sette A., et al. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 2003, 77(February (4)):2663-2674.
19. Wilson C.C., Palmer B., Southwood S., Sidney J., Higashimoto Y., Appella E., et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 2001, 75(May (9)):4195-4207.
20. Alexander J., del Guercio M.F., Frame B., Maewal A., Sette A., Nahm M.H., et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine 2004, 22(June (19)):2362-2367.
21. Altfeld M., Rosenberg E.S. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 2000, 12(August (4)):375-380.
22. Kumamoto Y., Mattei L.M., Sellers S., Payne G.W., Iwasaki A. CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A 2011, 108(May (21)):8749-8754.
23. Sidney J., Peters B., Frahm N., Brander C., Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008, 9:1.
24. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27(May (25-26)):3306-3312.
25. Ensoli B., Bellino S., Tripiciano A., Longo O., Francavilla V., Marcotullio S., et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010, 5(11):e13540.
26. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006, 24(May (20)):4343-4353.
27. Pajot A., Michel M.L., Fazilleau N., Pancre V., Auriault C., Ojcius D.M., et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004, 34(November (11)):3060-3069.
28. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Lower M., et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59(October (10)):1489-1501.
29. Bode G., Clausing P., Gervais F., Loegsted J., Luft J., Nogues V., et al. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods 2010, 62(November-December (3)):196-220.
30. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997, 185(June (12)):2043-2051.
31. Cobb A., Roberts L.K., Palucka A.K., Mead H., Montes M., Ranganathan R., et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods 2011, 365(February (1-2)):27-37.
32. De Rose R., Fernandez C.S., Smith M.Z., Batten C.J., Alcantara S., Peut V., et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 2008, 4(May (5)):e1000055.
33. Huang X.L., Fan Z., Colleton B.A., Buchli R., Li H., Hildebrand W.H., et al. Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons. J Virol 2005, 79(March (5)):3052-3062.
34. Sabbaj S., Bansal A., Ritter G.D., Perkins C., Edwards B.H., Gough E., et al. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J Acquir Immune Defic Syndr 2003, 33(August (4)):426-438.
35. Zhang Q.J., Gavioli R., Klein G., Masucci M.G. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci U S A 1993, 90(March (6)):2217-2221.
36. Brander C., Walker B.D. Systematic identification of optimal HIV-1 CTL epitopes, 1997. HIV Molecular Immunology Database 1997, p. IV-1 to IV-11.
37. Shiga H., Shioda T., Tomiyama H., Takamiya Y., Oka S., Kimura S., et al. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 1996, 10(September (10)):1075-1083.